Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Brain Sci
2021 Mar 30;114:. doi: 10.3390/brainsci11040441.
Show Gene links
Show Anatomy links
Dissecting the Molecular Determinants of GABAA Receptors Current Rundown, a Hallmark of Refractory Human Epilepsy.
Cifelli P
,
Di Angelantonio S
,
Alfano V
,
Morano A
,
De Felice E
,
Aronica E
,
Ruffolo G
,
Palma E
.
???displayArticle.abstract??? GABAA receptors-(Rs) are fundamental for the maintenance of an efficient inhibitory function in the central nervous system (CNS). Their dysfunction is associated with a wide range of CNS disorders, many of which characterized by seizures and epilepsy. Recently, an increased use-dependent desensitization due to a repetitive GABA stimulation (GABAA current rundown) of GABAARs has been associated with drug-resistant temporal lobe epilepsy (TLE). Here, we aimed to investigate the molecular determinants of GABAA current rundown with two different heterologous expression systems (Xenopus oocytes and human embryonic kidney cells; HEK) which allowed us to manipulate receptor stoichiometry and to study the GABAA current rundown on different GABAAR configurations. To this purpose, we performed electrophysiology experiments using two-electrode voltage clamp in oocytes and confirming part of our results in HEK. We found that different degrees of GABAA current rundown can be associated with the expression of different GABAAR β-subunits reaching the maximum current decrease when functional α1β2 receptors are expressed. Furthermore, the blockade of phosphatases can prevent the current rundown observed in α1β2 GABAARs. Since GABAAR represents one important therapeutic target in the treatment of human epilepsy, our results could open new perspectives on the therapeutic management of drug-resistant patients showing a GABAergic impairment.
Figure 1. GABA current rundown in oocytes expressing different GABAAR subunit combinations. (A) Time course of GABA current rundown relative to α1β2γ2(â), α1β1(â), α1β2(â), α1β3(â) GABAARs. GABA currents are normalized to that elicited by the first GABA application (IGABA: â, 2720 ± 280 nA, n = 24; â, 1264 ± 106 nA, n = 25; â, 749±130 nA, n = 95; â, 875 ± 139 nA, n = 30). (B) Representative evoked GABA currents at first, sixth GABA application of the rundown protocol and relative washout (black bars) (C) The bars represent mean ± SEM of GABA current rundown values in groups of oocytes expressing different GABA receptor subunit combinations as indicated. GABA current (%) has been calculated as the reduction in peak amplitude of the 6th GABA-evoked current as percent of the 1st current after the rundown protocol (six 10-s applications of 500 μM GABA at 40-s intervals). Statistical significance among the four groups was assessed with Kruskal-Wallis One Way Analysis of Variance on ranks with pairwise multiple comparison procedures (Dunnâs Method). * p < 0.05.
Figure 2. GABA current rundown in HEK cells transfected with GABAARs cDNAs. Time course of averaged responses (±SEM; p < 0.05, MannâWhitney rank sum test) obtained in HEK cells expressing either α1β2γ2 (n = 11, â) or α1β2 (n = 13, â) GABAARs. In each cell, peak amplitude of subsequent responses was expressed as a percentage of the first response of the rundown protocol.
Figure 3. Effect of okadaic acid on GABA current rundown in oocytes expressing α1β2 GABAARs. The bars represent mean ± SEM of GABA current rundown values before (red bar) and after (grey bar) the intracellular injection of okadaic acid (≈20 nM final concentration) n = 11; * p < 0.001, Wilcoxon Signed Rank Test. Inset: representative currents in one oocyte at first and sixth GABA application of rundown protocol and relative recovery after application of okadaic acid.
Figure 4. GABAARs affinity in oocytes expressing α1β2γ2 GABAARs or α1β2 GABAARs. GABA doseâcurrent relationships in oocytes injected with α1β2γ2 (â) or α1β2 cDNAs (â). Peak currents were normalized to the current obtained with 1 mM GABA and refer to 6 oocytes each point. EC50 and nH were 7.36 ± 0.47 μM and 1.0 ± 0.04 for α1β2 receptors; 5.0 ± 0.15 μM and 0.99 ± 0.1 for α1β2γ2; p > 0.05, MannâWhitney rank sum test.
Berg,
Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.
2010, Pubmed
Berg,
Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.
2010,
Pubmed
Brandon,
A-kinase anchoring protein 79/150 facilitates the phosphorylation of GABA(A) receptors by cAMP-dependent protein kinase via selective interaction with receptor beta subunits.
2003,
Pubmed
Brandon,
GABAA receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway.
2000,
Pubmed
Brooks-Kayal,
Human neuronal gamma-aminobutyric acid(A) receptors: coordinated subunit mRNA expression and functional correlates in individual dentate granule cells.
1999,
Pubmed
Chuang,
Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy.
2018,
Pubmed
Cifelli,
Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy.
2013,
Pubmed
Cifelli,
Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission?
2020,
Pubmed
Connolly,
Cell surface stability of gamma-aminobutyric acid type A receptors. Dependence on protein kinase C activity and subunit composition.
1999,
Pubmed
Di Angelantonio,
Adenosine A2A receptor induces protein kinase A-dependent functional modulation of human (alpha)3(beta)4 nicotinic receptor.
2011,
Pubmed
Farrant,
Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors.
2005,
Pubmed
Gambardella,
Pharmacological modulation in mesial temporal lobe epilepsy: Current status and future perspectives.
2016,
Pubmed
Grabenstatter,
Molecular pathways controlling inhibitory receptor expression.
2012,
Pubmed
Hernandez,
A structural look at GABAA receptor mutations linked to epilepsy syndromes.
2019,
Pubmed
Jacob,
GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition.
2008,
Pubmed
Kittler,
Modulation of GABAA receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic inhibition.
2003,
Pubmed
Kwan,
Drug-resistant epilepsy.
2011,
Pubmed
Li,
Functional rundown of gamma-aminobutyric acid(A) receptors in human hypothalamic hamartomas.
2011,
Pubmed
,
Xenbase
Löscher,
Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.
2020,
Pubmed
Loup,
Selective alterations in GABAA receptor subtypes in human temporal lobe epilepsy.
2000,
Pubmed
Mazzuferi,
Enhancement of GABA(A)-current run-down in the hippocampus occurs at the first spontaneous seizure in a model of temporal lobe epilepsy.
2010,
Pubmed
,
Xenbase
Morano,
Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects.
2020,
Pubmed
Morano,
Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.
2016,
Pubmed
,
Xenbase
Palma,
The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation.
2007,
Pubmed
,
Xenbase
Palma,
BDNF modulates GABAA receptors microtransplanted from the human epileptic brain to Xenopus oocytes.
2005,
Pubmed
,
Xenbase
Palma,
GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) "phasic" receptors.
2007,
Pubmed
,
Xenbase
Palma,
Microtransplantation of membranes from cultured cells to Xenopus oocytes: a method to study neurotransmitter receptors embedded in native lipids.
2003,
Pubmed
,
Xenbase
Palma,
Modulation of GABAA Receptors in the Treatment of Epilepsy.
2017,
Pubmed
Palma,
Phosphatase inhibitors remove the run-down of gamma-aminobutyric acid type A receptors in the human epileptic brain.
2004,
Pubmed
,
Xenbase
Palma,
Expression of human epileptic temporal lobe neurotransmitter receptors in Xenopus oocytes: An innovative approach to study epilepsy.
2002,
Pubmed
,
Xenbase
Pirker,
Increased expression of GABA(A) receptor beta-subunits in the hippocampus of patients with temporal lobe epilepsy.
2003,
Pubmed
Ragozzino,
Rundown of GABA type A receptors is a dysfunction associated with human drug-resistant mesial temporal lobe epilepsy.
2005,
Pubmed
,
Xenbase
Roseti,
Fractalkine/CX3CL1 modulates GABAA currents in human temporal lobe epilepsy.
2013,
Pubmed
,
Xenbase
Roseti,
Erythropoietin Increases GABAA Currents in Human Cortex from TLE Patients.
2020,
Pubmed
,
Xenbase
Ruffolo,
Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions.
2016,
Pubmed
,
Xenbase
Ruffolo,
Modulation of GABAergic dysfunction due to SCN1A mutation linked to Hippocampal Sclerosis.
2020,
Pubmed
Ruffolo,
Rare Diseases of Neurodevelopment: Maintain the Mystery or Use a Dazzling Tool for Investigation? The Case of Rett Syndrome.
2020,
Pubmed
,
Xenbase
Ruffolo,
A novel GABAergic dysfunction in human Dravet syndrome.
2018,
Pubmed
,
Xenbase
Ruffolo,
A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy.
2018,
Pubmed
,
Xenbase
Sigel,
Impact of subunit positioning on GABAA receptor function.
2006,
Pubmed
Sigel,
Structure, function, and modulation of GABA(A) receptors.
2012,
Pubmed
Soukupová,
Impairment of GABA release in the hippocampus at the time of the first spontaneous seizure in the pilocarpine model of temporal lobe epilepsy.
2014,
Pubmed
Talos,
Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.
2012,
Pubmed
Tsunashima,
GABA(A) receptor subunits in the rat hippocampus III: altered messenger RNA expression in kainic acid-induced epilepsy.
1997,
Pubmed
